细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂治疗激素受体阳性、人表皮生长因子受体2（HER2）非扩增转移性乳腺癌患者的新数据及未来方向

Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer.

作者信息

Lim Elgene, Beith Jane, Boyle Frances, de Boer Richard, Hui Rina, McCarthy Nicole, Redfern Andrew, Wade Theresa, Woodward Natasha

机构信息

St.Vincent's Clinical School, University of New South Wales, Darlinghurst, NSW, 2010, Australia.

Garvan Institute of Medical Research, Darlinghurst, NSW, 2010, Australia.

出版信息

Asia Pac J Clin Oncol. 2018 Oct;14 Suppl 4:12-21. doi: 10.1111/ajco.13065.

DOI:10.1111/ajco.13065

PMID:30288929

Abstract

Cyclin-dependent kinase (CDK4/6) inhibitors in combination with endocrine therapy are currently the optimal first line treatment for hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) non-amplified metastatic breast cancer (MBC). However, not all patients benefit from this treatment and all patients will inevitably progress. Identifying therapeutic strategies in this setting is therefore of immediate clinical importance. We present an overview of the mechanisms of resistance to CDK4/6 inhibitors and review potential biomarkers that may guide therapy selection. We also discuss the use of CDK4/6 inhibitors in the context of non-HR-positive/HER2-non-amplified breast cancer and in combination with therapies other than endocrine therapy.

摘要

细胞周期蛋白依赖性激酶（CDK4/6）抑制剂联合内分泌治疗目前是激素受体（HR）阳性、人表皮生长因子受体2（HER2）非扩增转移性乳腺癌（MBC）的最佳一线治疗方案。然而，并非所有患者都能从这种治疗中获益，所有患者最终都不可避免地会出现疾病进展。因此，确定这一情况下的治疗策略具有直接的临床重要性。我们概述了对CDK4/6抑制剂耐药的机制，并综述了可能指导治疗选择的潜在生物标志物。我们还讨论了CDK4/6抑制剂在非HR阳性/HER2非扩增乳腺癌中的应用，以及与内分泌治疗以外的其他疗法联合使用的情况。